Denali Therapeutics
šŗšøUnited States
- Country
- šŗšøUnited States
- Ownership
- -
- Employees
- 445
- Market Cap
- -
- Introduction
Denali Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of a portfolio of product candidates for neurodegenerative diseases. Its product pipeline includes LRRK2, RIPK1, TREM2, and Tau. The company was founded by Ryan J. Watts, Marc Tessier-Lavigne, and Alexander Schuth on October 14, 2013 and is headquartered in San Francisco, CA.
Denali Therapeutics Reports First Quarter 2024 Financial
Denali Therapeutics reported Q1 2024 financials, highlighting progress in neurodegenerative and lysosomal storage disease treatments. Key updates include positive clinical data for tividenofusp alfa in MPS II, DNL343's Phase 2/3 ALS trial enrollment completion, and advancements in Parkinsonās and Alzheimerās therapies. The company raised $500M in financing, focusing on BBB-crossing therapeutics.
Denali's Hunter Syndrome Candidate Receives Orphan Drug Designation
Denali Therapeutics' DNL310, a treatment for Hunter Syndrome (MPS II), received FDA orphan drug and rare pediatric disease designations. The drug, using proprietary ETV technology, aims to address neurological symptoms untreatable by current therapies. Denali plans a phase I/II study in 2020, with potential for marketing exclusivity and tax credits. Shares rose 1.5% post-announcement.
Ā© Copyright 2025. All Rights Reserved by MedPath